A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 11, 2014, Pages 1737-1743

  Herrera, Alex F ^a   Kim, Haesook T ^a   Bindra, Bhavjot ^a   Jones, Kyle T ^a   Alyea, Edwin P ^a   Armand, Philippe ^a   Cutler, Corey S ^a   Ho, Vincent T ^a   Nikiforow, Sarah ^a   Blazar, Bruce R ^b   Ritz, Jerome ^a   Antin, Joseph H ^a   Soiffer, Robert J ^a   Koreth, John ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Chronic graft versus host disease; Graft versus host disease; Hematopoietic stem cell transplantation; Proteasome inhibition

Indexed keywords

BORTEZOMIB; PREDNISONE; PROTEASOME; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTHROPATHY; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; FASCIA DISEASE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPOTHESIS; IMMUNOMODULATION; LIVER DISEASE; MALE; MUSCLE DISEASE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; SKIN DISEASE; TREATMENT OUTCOME; CHRONIC DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; GRAFT VS HOST DISEASE; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BORTEZOMIB; CHRONIC DISEASE; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; PYRAZINES;

EID: 84908067774     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.06.040     Document Type: Article

References (45)

1. Perez-Simon J.A., Encinas C., Silva F., et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant 2008, 14:1163-1171.
2. Pidala J., Kurland B., Chai X., et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011, 117:4651-4657.
3. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
4. Koc S., Leisenring W., Flowers M.E., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002, 100:48-51.
5. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
6. Palombella V.J., Conner E.M., Fuseler J.W., et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci of U S A 1998, 95:15671-15676.
7. Wang X., Luo H., Chen H., et al. Role of proteasomes in T cell activation and proliferation. JImmunol 1998, 160:788-801.
8. Ghosh S., May M.J., Kopp E.B. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Ann Rev Immunol 1998, 16:225-260.
9. Finn P.W., Stone J.R., Boothby M.R., Perkins D.L. Inhibition of NF-kappa B-dependent T cell activation abrogates acute allograft rejection. JImmunol 2001, 167:5994-6001.
10. Sunwoo J.B., Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7:1419-1428.
11. Kaileh M., Sen R. NF-kappaB function in B lymphocytes. Immunol Rev 2012, 246:254-271.
12. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., et al. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica 2009, 94:975-983.
13. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107:3575-3583.
14. Nencioni A., Schwarzenberg K., Brauer K.M., et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006, 108:551-558.
15. Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 2004, 101:8120-8125.
16. Blanco B., Sanchez-Abarca L.I., Caballero-Velazquez T., et al. Depletion of alloreactive T-cells invitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens. Leuk Res 2011, 35:1412-1415.
17. Kim J.S., Lee J.I., Shin J.Y., et al. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates. Transplantation 2009, 88:1349-1359.
18. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009, 114:3956-3959.
19. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. JClin Oncol 2012, 30:3202-3208.
20. Mateos-Mazon J., Perez-Simon J.A., Lopez O., et al. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. Haematologica 2007, 92:1295-1296.
21. Todisco E., Sarina B., Castagna L., et al. Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib. Leuk Lymphoma 2007, 48:1015-1018.
22. El-Cheikh J., Michallet M., Nagler A., et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008, 93:455-458.
23. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. JClin Oncol 2004, 22:2108-2121.
24. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
25. Calhoun E.A., Welshman E.E., Chang C.H., et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003, 13:741-748.
26. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006, 12:252-266.
27. Koc S., Leisenring W., Flowers M.E., et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000, 96:3995-3996.
28. Martin P.J., Storer B.E., Rowley S.D., et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009, 113:5074-5082.
29. Arora M., Wagner J.E., Davies S.M., et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001, 7:265-273.
30. Martin P.J., Storer B.E., Carpenter P.A., et al. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:124-132.
31. Matsuoka K., Koreth J., Kim H.T., et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013, 5:179ra43.
32. Imanguli M.M., Cowen E.W., Rose J., et al. Comparative analysis of FoxP3 regulatory T Cells in the target tissues and blood in chronic graft versus host disease. Leukemia 2014, [Epub ahead of print]. doi:10.1038/leu.2014.92.
33. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009, 113:3865-3874.
34. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
35. Arai S., Sahaf B., Narasimhan B., et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012, 119:6145-6154.
36. Cutler C., Kim H.T., Bindra B., et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 2013, 122:1510-1517.
37. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
38. Miklos D.B., Kim H.T., Zorn E., et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004, 103:353-359.
39. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
40. Zorn E., Miklos D.B., Floyd B.H., et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. JExp Med 2004, 199:1133-1142.
41. Zorn E., Kim H.T., Lee S.J., et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005, 106:2903-2911.
42. Matsuoka K., Kim H.T., McDonough S., et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. JClin Invest 2010, 120:1479-1493.
43. Koreth J., Matsuoka K., Kim H.T., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. NEng J Med 2011, 365:2055-2066.
44. Kroger N., Zabelina T., Ayuk F., et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006, 34:770-775.
45. van de Donk N.W., Kroger N., Hegenbart U., et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006, 107:3415-3416.